Damora Therapeutics (DMRA) Other Non Operating Income (2019 - 2025)
Damora Therapeutics posted quarterly Other Non Operating Income of $3000.0 for Q4 2025, down 97.6% year-on-year from $125000.0 in Q4 2024, and up 115.79% on a QoQ basis from -$19000.0 in Q3 2025.
Damora Therapeutics (DMRA) has 7 years of Other Non Operating Income data on file, last reported at $3000.0 in Q4 2025.
- For the quarter ending Q4 2025, Other Non Operating Income fell 97.6% year-over-year to $3000.0; the trailing twelve-month figure through Mar 2026 stood at -$78000.0 (down 1660.0% YoY), and the FY2025 full-year result was -$84000.0, down 566.67% from the prior year.
- Other Non Operating Income for Q4 2025 stood at $3000.0, up from -$19000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $208000.0 in Q3 2021 and bottomed at -$828000.0 in Q4 2022.
- The 5-year median for Other Non Operating Income is -$12500.0 (2025), against an average of -$50650.0.
- The widest annual swing landed in 2022, when Other Non Operating Income tumbled 2955.17%; it then soared 351.85% in 2024.
- A 5-year view of Other Non Operating Income shows it stood at $29000.0 in 2021, then sank by 2955.17% to -$828000.0 in 2022, then jumped by 74.88% to -$208000.0 in 2023, then soared by 160.1% to $125000.0 in 2024, then slumped by 97.6% to $3000.0 in 2025.
- The last three Other Non Operating Income figures came in at $3000.0 (Q4 2025), -$19000.0 (Q3 2025), and -$62000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Damora Therapeutics | 853.36 Mn | 650.97 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3,000.00 |
| Sep 30, 2025 | -19,000.00 |
| Jun 30, 2025 | -62,000.00 |
| Mar 31, 2025 | -6,000.00 |
| Dec 31, 2024 | 125,000.00 |
| Sep 30, 2024 | -182,000.00 |
| Jun 30, 2024 | 68,000.00 |
| Mar 31, 2024 | 7,000.00 |
| Dec 31, 2023 | -208,000.00 |
| Sep 30, 2023 | -26,000.00 |
| Jun 30, 2023 | -27,000.00 |
| Mar 31, 2023 | 64,000.00 |
| Dec 31, 2022 | -828,000.00 |
| Sep 30, 2022 | -329,000.00 |
| Jun 30, 2022 | 148,000.00 |
| Mar 31, 2022 | -60,000.00 |
| Dec 31, 2021 | 29,000.00 |
| Sep 30, 2021 | 208,000.00 |
| Jun 30, 2021 | -86,000.00 |
| Mar 31, 2021 | 168,000.00 |
| Dec 31, 2020 | -275,000.00 |
| Sep 30, 2020 | -1.49 Mn |
| Jun 30, 2020 | 403,000.00 |
| Mar 31, 2020 | 156,000.00 |
| Dec 31, 2019 | -118,000.00 |
| Sep 30, 2019 | 337,000.00 |